MET and gastric cancer: Patients selected by MET protein overexpression and MET amplification in gastroesophageal cancers [20, 21], MET germline mutations in papillary renal cell cancer [17], and chromosome polyploidy in gastric cancer [22] have been associated with response to MET inhibitors.